ArticleIrish journal of medical science2026
Determinants of relapse and delayed convalescence in patients with Brucellosis: a one-year prospective follow-up.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrucellosis is a globally occurring zoonotic infectious disease that causes severe illness in both humans and farm animals.
aimsThis study aimed to investigate the factors associated with relapse and delayed convalescence in patients with brucellosis.
methodsThis prospective, single-center study included patients diagnosed with brucellosis who presented to our clinic between January 2022 and January 2023. Patients were categorized into two groups based on relapse (- / +) and delayed convalescence (- / +). Clinical and laboratory findings were compared between the two groups.
resultsOf these 101 patients, 58.4% (n = 59) were male, and the mean age was 41.8 ± 14.6 years. Relapse occurred in 16 patients (15.8%). Relapse was observed in 68.7% (n = 11/16) of the patients in the first 6 months. In patients with relapse, smoking (p = 0.008, OR = 8.24, 95% CI:1.71-39.5), headache (p = 0.04, OR = 4.93, 95% CI:1.07-22.7) and increased lymphocyte percentage (> 48) (p = 0.004, OR = 11.9, 95% CI:2.21-64.7) were independent predictors associated with relapse. Delayed convalescence was observed in 17 of 85 patients (20%) who received successful treatment. Myalgia (100.0% vs. 76.5%, p = 0.026) and increased lymphocyte percentage (> 48) (23.5% vs. 7.4%, p = 0.048) were more common in patients with delayed convalescence than in those without. However, these parameters were not significant in multivariate analysis.
conclusionsBrucellosis patients who smoking, experience headaches, and have a lymphocyte count above 48% should be monitored for at least 6 months after treatment to assess the risk of relaps. It is important to note that symptoms may not completely resolve after treatment in patients with a lymphocyte count above 48% and myalgia.
Indexed as
Identifiers
42776450What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.